Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Charcot foot is a complication of diabetes characterized by progressive damage to bones, soft tissues, and tendons, leading to dislocation in the ankle and foot. It is often poorly understood and underdiagnosed due to non-specific signs. This study follows a group of patients with chronic Charcot foot in France to examine changes in quality of life over two years and identify factors that predict worse outcomes within this population. Participants will be observed without any experimental treatment. They will complete various questionnaires including SF-36, FAAM-F, PHQ-9, PHQ-2, and a simplified EPICES score to assess quality of life, foot and ankle function, and mental health. The study will also track radiologic changes in foot deformities and monitor diabetes complications and comorbidities at baseline, 12 months, and 24 months. During the two-year follow-up, participants will undergo evaluations including quality of life and functional questionnaires at the start, one year, and two years. Imaging studies will assess foot bone and joint deformities, and medical records will be reviewed for diabetes-related complications, hospitalizations, wounds, infections, amputations, and psychological status. The study aims to better understand the factors impacting quality of life and foot health in chronic Charcot foot patients over time.
Actively Recruiting
Researchers are evaluating the combination of baxdrostat and dapagliflozin compared with dapagliflozin alone in adults aged 40 years and older who have type 2 diabetes, established cardiovascular disease, a history of hypertension with elevated systolic blood pressure, and at least one additional risk factor for heart failure. This phase III trial aims to assess whether adding baxdrostat can reduce the risk of heart failure events or cardiovascular death. Participants will be randomly assigned to receive either baxdrostat with dapagliflozin or placebo with dapagliflozin. Those not currently on SGLT2 inhibitors or treated for less than 4 weeks will enter a run-in period taking dapagliflozin alone for 4 to 6 weeks before randomization. Doses of baxdrostat may be increased if criteria are met. Study visits occur at 2, 4, 8, 16, and 34 weeks after randomization and then approximately every 4 months until the study ends when enough cardiovascular events have occurred. During the study, participants will have regular assessments including blood pressure and laboratory tests to monitor safety and efficacy. If participants stop the blinded study treatment early, they may continue open-label dapagliflozin. The main outcome is to see if the combination reduces heart failure events or cardiovascular death compared to dapagliflozin alone, with follow-up lasting up to 38 months. Data collection and scheduled visits will continue throughout the study period.
Actively Recruiting
Diabetic foot ulcer DFU is a common and serious complication in people with diabetes, often leading to lower-limb amputation and linked to decreased quality of life and increased health care costs. This research aims to better understand why patients with DFU have a higher risk of premature death, exploring factors beyond cardiovascular disease such as inflammation, infections, and cancers. The study is a prospective, observational, multi-center cohort conducted in France. Adults with diabetes and DFU will be followed for up to 5 years to measure outcomes including mortality rates, causes of death, and prognostic factors. The study will include a 3-year enrollment period starting in 2020. Researchers will also assess changes in health-related quality of life and the economic burden of DFU using healthcare claims data. Participants will be monitored regularly over 5 years or until death. Researchers will collect data on survival without active or recurrent DFU, major limb and vascular events, and overall health status. The study will provide important data on the course of DFU and its impact on patients lives and health care systems.